Table I.
Patient characteristics (n=308).
| Characteristics | No. (%) |
|---|---|
| age, years [median (range)] | 59.0 (26–91) |
| Histology | |
| IDC | 282 (91.6) |
| ILC | 5 (1.6) |
| Others | 21 (6.8) |
| pT stage | |
| T1 | 226 (73.4) |
| T2 | 67 (21.8) |
| T3 | 1 (0.3) |
| T4 | 14 (4.5) |
| Nodal status | |
| Negative | 288 (93.5) |
| Positive | 20 (6.5) |
| Nuclear grade | |
| I | 38 (12.3) |
| II | 214 (69.5) |
| III | 32 (10.4) |
| Unknown | 24 (7.8) |
| Lymphovascular invasion | |
| Negative | 57 (18.5) |
| Positive | 248 (80.5) |
| Unknown | 3 (1.0) |
| Progesterone receptor status | |
| Negative | 50 (16.2) |
| Positive | 257 (83.5) |
| Unknown | 1 (0.3) |
| Ki67 labeling index, % [median (range)] | 15.2 (0.0–77.8) |
| p53 status | |
| Positive | 83 (26.9) |
| Negative | 225 (73.1) |
| Type of surgery | |
| Breast-conserving surgery | 221 (71.8) |
| Modified radical mastectomy | 87 (28.2) |
| Endocrine therapy | |
| Tamoxifen | 88 (28.5) |
| Tamoxifen + Gn-RH agonist | 40 (13.0) |
| Gn-RH agonist | 3 (1.0) |
| Anastrozole | 97 (31.5) |
| Letrozole | 76 (24.7) |
| Exemestane | 4 (1.3) |
| Chemotherapy | 86 (27.9) |
| Oral 5-FU | 4 (1.3) |
| Anthracycline | 29 (9.4) |
| Anthracycline + taxane | 35 (11.4) |
| CMF | 2 (0.6) |
| TC | 16 (5.2) |
| Recurrence | |
| Local | 11 (3.6) |
| Distant | 13 (4.2) |
| No event | 284 (92.2) |
| Death | 8 (2.5) |
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Gn-RH, gonadotrophin-releasing hormone; 5-FU, 5-fluorouracil; CMF, cyclophosphamide, methotrexate and 5-fluorouracil; TC, docetaxel and cyclophosphamide.